Podcasts about adverse events

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:An overview of ADC structure and mechanism of actionA topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor typesAn in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategiesEditor's note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. Program faculty:Allison Butts, PharmD, BCOPPharmacist Manager, OncologyClinical Pharmacist, Breast OncologyUK HealthCareMarkey Cancer CenterLexington, KentuckyDanielle Roman, PharmD, BCOPManager, Oncology Clinical Pharmacy ServicesAllegheny Health NetworkPittsburgh, PennsylvaniaProgram page:https://bit.ly/4lr7cT6

Welcome back to Ditch the Labcoat, the show where we challenge assumptions in medicine and seek out the systems, stories, and science that truly shape healthcare. In today's episode, we're joined by Martin Bromiley: airline captain, human factors champion, and founder of the Clinical Human Factors Group.But before he became a global advocate for patient safety, Martin faced unimaginable tragedy when his wife, Elaine, died following what was supposed to be a routine surgical procedure in 2005.Martin's journey isn't just about personal loss—it's about his relentless quest to understand why a well-trained, technically proficient medical team could still fall short in a critical moment. Drawing lessons from aviation, where errors spark investigation and learning rather than resignation, Martin became a pivotal force in bringing the science of human factors—a field all about understanding how people interact with their environment, teams, and tools—into the world of healthcare.In this conversation, we explore not just the events that launched his mission, but the broader issues of humility, communication, and system design. We talk about “can't intubate, can't ventilate” scenarios, reflect on the evolution of patient safety culture, and crack open the stubborn problem of medical hierarchy. Martin's story isn't just one of systemic frustration; it's also one of hope and tangible change.So whether you're a healthcare professional, a patient, or just someone curious about how lives can be saved not simply by skill, but by safer systems—this episode is a gripping, essential listen. Plug in and prepare to have your ideas about medicine, teamwork, and learning turned upside down.Episode HighlightsHumility in Healthcare – Humility is vital for professionals to learn, grow, and stay open to feedback, ultimately improving patient safety.Communication Saves Lives – Miscommunications in critical situations can be fatal; clear, assertive dialogue and defined roles are essential in emergencies.Teamwork Over Hierarchy – Breaking down rigid medical hierarchies empowers every team member to speak up for patient safety.Design Smarter Systems – Systems must be created to make errors less likely, whether via technology, checklists, or better equipment design. Independent Case Reviews – Conducting external, impartial reviews after adverse events helps identify root causes and leads to improvements.Small Changes, Big Impact – Reducing steps in processes, standardizing equipment, or tweaking procedures can greatly decrease error risks.Continuous Improvement Mindset – Perfection isn't possible, but aiming to get a little better every day is the key to safer healthcare for all.Episode Timestamps 6:15 — Turning Point: Embracing Human Factors 7:19 — "Science Overlooked in Healthcare" 11:01 — Intensive Care Transfer Decision 14:51 — Receptionist Sparks Important Meeting 18:11 — Evolution of Case Review Processes 22:27 — "Human Factors in Healthcare Initiative" 25:02 — Origin of Aviation Safety Protocols 28:28 — Enhancing Safety in Drug Handling 30:30 — Medication Errors and Design Flaws 33:49 — Promoting Human Factors in Healthcare 38:04 — Team Leadership in Medical Procedures 42:51 — Healthcare Pressures and Consequences 44:47 — "Concerns Over Arrogant Healthcare Professionals" 50:16 — Striving for Continuous Improvement in Healthcare 52:36 — Progress in Healthcare Culture ShiftDISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.    Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. 

Immune-related adverse events (AEs) are becoming more frequent in oncology patients receiving immunotherapy. To better understand emerging trends and education needs, the Association of Cancer Care Centers (ACCC) developed the Immuno-Oncology Census as part of its ongoing commitment to sharing up-to-date strategies for managing adverse events. In this episode, CANCER BUZZ speaks with Bat-ami Gordon, clinical research PhD candidate at the Icahn School of Medicine at Mount Sinai, who discusses best practices for cancer care providers to identify immune-related AEs caused by immunotherapy.   “Understanding the best practices for identification is going to be the best way we can start to implement better treatments for these immune-related adverse events.” – Bat-ami Gordon   Bat-ami Gordon Clinical Research PhD Candidate  Icahn School of Medicine Mount Sinai New York, NY      Additional Reading/Sources   Icahn School of Medicine at Mount Sinai ACCC Immune-Related Adverse Events Resources Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors ACCC Immuno-Oncology Census

On this week's episode of CMDA Matters, we're joined by Ryan T. Anderson, Ph.D., President of the Ethics and Public Policy Center, and Jamie Bryan Hall, EPPC's Director of Data Analysis, for an important conversation about the safety of the abortion pill, mifepristone. Together, they unpack findings from a groundbreaking EPPC study analyzing more than 865,000 insurance claims – the largest-known study of its kind. This episode explores troubling trends in serious adverse events related to abortion pill use, including hospitalizations, infections, misdiagnoses, and coercion.

With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care.Read the full series here:https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology?dgcid=buzzsprout_icw_podcast_13-06-25_lanhaeadverseevents25_lanhaeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Garima Sharma from Inova Fairfax, Virginia, US. They discuss adverse pregnancy outcomes and how they can increase subsequent cardiovascular risk - and importantly how we can lower this risk. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks!   Link to published paper: https://heart.bmj.com/content/111/2/83

Dr. James A. Thorp is a board-certified obstetrician-gynecologist and maternal-fetal medicine specialist with over 44 years of clinical experience. A U.S. veteran and widely published physician, he has testified internationally, served as a journal peer reviewer, Board Member of the Society for Maternal-Fetal Medicine, and Examiner for the American Board of Obstetrics and Gynecology. He is the author of “Sacrifice: How the Deadliest Vaccine in History Targeted the Most Vulnerable.” Dr. Thorp also serves as the Chief of Maternal Medicine and Prenatal Medicine for the Wellness Company.  Follow Dr. James A. Thorp on X: @jathorpmfm VISIT: https://drjamesthorp.com/ & https://abrg.org ORDER: https://sacrifice2024.com/

Dr Sorcha O'Meara graduated from UCD in 2015 and quickly decided to pursue a career in Urology. Dr O'Meara is currently a specialist registrar in urology and is currently completing a PhD. Dr O'Meara has a keen interest human factors and the non-surgical skills surgeons need to succeed. Dr O'Meara lives in Dublin with her husband, son and dog and when Sorcha is not in work she enjoys swimming or hiking. 

In this episode of Right to Life Radio, John Gerardi dives into a groundbreaking study exposing the abortion pill's dangers, revealing an 11% rate of serious adverse events—far higher than the FDA's claims. Joined by Linda Talia, the show shares poignant "Stories from the Sidewalk," capturing the heartbreak and hope of ministering outside Planned Parenthood. Jonathan Keller breaks down California's push to shield abortion pill access, spotlighting legislative gaslighting despite hard data. It's a raw look at life, science, and politics colliding.

In this episode Laura Sigman, MD, FAAP, discusses having conversations with patients about adverse medical events. David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Rebekah Levine Coley, PhD, about new trends in adolescents' risky behaviors. For resources go to aap.org/podcast.

In this episode of Nurse Converse, Maggie Ortiz and RaDonda Vaught explore the lasting impact of RaDonda's case, focusing on the Board of Nursing's role, the legal risks nurses face, and the complexities of due process following medical errors. They discuss the urgent need for accountability, legal education, and support for nurses navigating an often opaque regulatory system—all while keeping patient safety at the center. Join us for a candid conversation about the legal challenges nurses face and what must change to better protect both nurses and patients.Jump Ahead to Listen:[01:41] Boards of nursing investigations.[04:16] Types of law for nurses.[09:54] Medication-related patient harm.[12:13] Medication administration policy violation.[16:07] Legal rights for nurses.[20:14] Protecting the public vs. nurses.[25:03] Administrative law for nurses.[29:35] Oversight in nursing investigations.Connect with Maggie LinkedIn and on social media:Instagram: @advocates4nursesTikTok: @advocates4nursesFor more information, full transcript and videos visit Nurse.org/podcastJoin our newsletter at nurse.org/joinInstagram: @nurse_orgTikTok: @nurse.orgFacebook: @nurse.orgYouTube: Nurse.org

In today's episode, Dr. Pierce Salguero sits down with Miguel Farias, an experimental psychologist and researcher of religion, spirituality, and cognition. Together we try to get to the bottom of whether meditation is actually good for you through a comparison of Miguel's research on the adverse effects of meditation with my research on Asian notions of meditation sickness. Along the way, we discuss the limitations of modern Western understandings of consciousness, and explore whether we can develop a more expansive, multifaceted understanding of altered states both pleasant and unpleasant. If you want to hear scholars and practitioners engaging in deep conversations about the dark side of Asian religions and medicines, then subscribe to Black Beryl wherever you get your podcasts. You can also check out our members-only benefits on blackberyl.substack.com. Enjoy the show! Resources mentioned: Miguel Farias and Catherine Wikholm, The Buddha Pill: Can Meditation Change You? (2019). Miguel Farias, Oxford Handbook of Meditation (2022). Miguel Farias et al, “Adverse Events in Meditation Practices and Meditation-based Therapies: A Systematic Review” (2021). Pierce Salguero, “‘Meditation Sickness' in Medieval Chinese Buddhism and the Contemporary West” (2023). Peter Berger, The Homeless Mind (1973). Joseph Henrich et al. article on the Müller-Lyer illusion (2010). The source for the term “monophasic bias” is apparently Charles Laughlin's chapter “Transpersonal Anthropology” in Roger Walsh's book Paths Beyond Ego (1993). Pierce Salguero, A Lamp Unto Yourself (2025). Resources provided by the interviewee on blackberyl.substack.com: Introduction to the Oxford Handbook of Meditation Pierce Salguero is a transdisciplinary scholar of health humanities who is fascinated by historical and contemporary intersections between Buddhism, medicine, and crosscultural exchange. He has a Ph.D. in History of Medicine from the Johns Hopkins School of Medicine (2010), and teaches Asian history, medicine, and religion at Penn State University's Abington College, located near Philadelphia. www.piercesalguero.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In today's episode, Dr. Pierce Salguero sits down with Miguel Farias, an experimental psychologist and researcher of religion, spirituality, and cognition. Together we try to get to the bottom of whether meditation is actually good for you through a comparison of Miguel's research on the adverse effects of meditation with my research on Asian notions of meditation sickness. Along the way, we discuss the limitations of modern Western understandings of consciousness, and explore whether we can develop a more expansive, multifaceted understanding of altered states both pleasant and unpleasant. If you want to hear scholars and practitioners engaging in deep conversations about the dark side of Asian religions and medicines, then subscribe to Black Beryl wherever you get your podcasts. You can also check out our members-only benefits on blackberyl.substack.com. Enjoy the show! Resources mentioned: Miguel Farias and Catherine Wikholm, The Buddha Pill: Can Meditation Change You? (2019). Miguel Farias, Oxford Handbook of Meditation (2022). Miguel Farias et al, “Adverse Events in Meditation Practices and Meditation-based Therapies: A Systematic Review” (2021). Pierce Salguero, “‘Meditation Sickness' in Medieval Chinese Buddhism and the Contemporary West” (2023). Peter Berger, The Homeless Mind (1973). Joseph Henrich et al. article on the Müller-Lyer illusion (2010). The source for the term “monophasic bias” is apparently Charles Laughlin's chapter “Transpersonal Anthropology” in Roger Walsh's book Paths Beyond Ego (1993). Pierce Salguero, A Lamp Unto Yourself (2025). Resources provided by the interviewee on blackberyl.substack.com: Introduction to the Oxford Handbook of Meditation Pierce Salguero is a transdisciplinary scholar of health humanities who is fascinated by historical and contemporary intersections between Buddhism, medicine, and crosscultural exchange. He has a Ph.D. in History of Medicine from the Johns Hopkins School of Medicine (2010), and teaches Asian history, medicine, and religion at Penn State University's Abington College, located near Philadelphia. www.piercesalguero.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/buddhist-studies

In today's episode, Dr. Pierce Salguero sits down with Miguel Farias, an experimental psychologist and researcher of religion, spirituality, and cognition. Together we try to get to the bottom of whether meditation is actually good for you through a comparison of Miguel's research on the adverse effects of meditation with my research on Asian notions of meditation sickness. Along the way, we discuss the limitations of modern Western understandings of consciousness, and explore whether we can develop a more expansive, multifaceted understanding of altered states both pleasant and unpleasant. If you want to hear scholars and practitioners engaging in deep conversations about the dark side of Asian religions and medicines, then subscribe to Black Beryl wherever you get your podcasts. You can also check out our members-only benefits on blackberyl.substack.com. Enjoy the show! Resources mentioned: Miguel Farias and Catherine Wikholm, The Buddha Pill: Can Meditation Change You? (2019). Miguel Farias, Oxford Handbook of Meditation (2022). Miguel Farias et al, “Adverse Events in Meditation Practices and Meditation-based Therapies: A Systematic Review” (2021). Pierce Salguero, “‘Meditation Sickness' in Medieval Chinese Buddhism and the Contemporary West” (2023). Peter Berger, The Homeless Mind (1973). Joseph Henrich et al. article on the Müller-Lyer illusion (2010). The source for the term “monophasic bias” is apparently Charles Laughlin's chapter “Transpersonal Anthropology” in Roger Walsh's book Paths Beyond Ego (1993). Pierce Salguero, A Lamp Unto Yourself (2025). Resources provided by the interviewee on blackberyl.substack.com: Introduction to the Oxford Handbook of Meditation Pierce Salguero is a transdisciplinary scholar of health humanities who is fascinated by historical and contemporary intersections between Buddhism, medicine, and crosscultural exchange. He has a Ph.D. in History of Medicine from the Johns Hopkins School of Medicine (2010), and teaches Asian history, medicine, and religion at Penn State University's Abington College, located near Philadelphia. www.piercesalguero.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

In today's episode, Dr. Pierce Salguero sits down with Miguel Farias, an experimental psychologist and researcher of religion, spirituality, and cognition. Together we try to get to the bottom of whether meditation is actually good for you through a comparison of Miguel's research on the adverse effects of meditation with my research on Asian notions of meditation sickness. Along the way, we discuss the limitations of modern Western understandings of consciousness, and explore whether we can develop a more expansive, multifaceted understanding of altered states both pleasant and unpleasant. If you want to hear scholars and practitioners engaging in deep conversations about the dark side of Asian religions and medicines, then subscribe to Black Beryl wherever you get your podcasts. You can also check out our members-only benefits on blackberyl.substack.com. Enjoy the show! Resources mentioned: Miguel Farias and Catherine Wikholm, The Buddha Pill: Can Meditation Change You? (2019). Miguel Farias, Oxford Handbook of Meditation (2022). Miguel Farias et al, “Adverse Events in Meditation Practices and Meditation-based Therapies: A Systematic Review” (2021). Pierce Salguero, “‘Meditation Sickness' in Medieval Chinese Buddhism and the Contemporary West” (2023). Peter Berger, The Homeless Mind (1973). Joseph Henrich et al. article on the Müller-Lyer illusion (2010). The source for the term “monophasic bias” is apparently Charles Laughlin's chapter “Transpersonal Anthropology” in Roger Walsh's book Paths Beyond Ego (1993). Pierce Salguero, A Lamp Unto Yourself (2025). Resources provided by the interviewee on blackberyl.substack.com: Introduction to the Oxford Handbook of Meditation Pierce Salguero is a transdisciplinary scholar of health humanities who is fascinated by historical and contemporary intersections between Buddhism, medicine, and crosscultural exchange. He has a Ph.D. in History of Medicine from the Johns Hopkins School of Medicine (2010), and teaches Asian history, medicine, and religion at Penn State University's Abington College, located near Philadelphia. www.piercesalguero.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/religion

In today's episode, Dr. Pierce Salguero sits down with Miguel Farias, an experimental psychologist and researcher of religion, spirituality, and cognition. Together we try to get to the bottom of whether meditation is actually good for you through a comparison of Miguel's research on the adverse effects of meditation with my research on Asian notions of meditation sickness. Along the way, we discuss the limitations of modern Western understandings of consciousness, and explore whether we can develop a more expansive, multifaceted understanding of altered states both pleasant and unpleasant. If you want to hear scholars and practitioners engaging in deep conversations about the dark side of Asian religions and medicines, then subscribe to Black Beryl wherever you get your podcasts. You can also check out our members-only benefits on blackberyl.substack.com. Enjoy the show! Resources mentioned: Miguel Farias and Catherine Wikholm, The Buddha Pill: Can Meditation Change You? (2019). Miguel Farias, Oxford Handbook of Meditation (2022). Miguel Farias et al, “Adverse Events in Meditation Practices and Meditation-based Therapies: A Systematic Review” (2021). Pierce Salguero, “‘Meditation Sickness' in Medieval Chinese Buddhism and the Contemporary West” (2023). Peter Berger, The Homeless Mind (1973). Joseph Henrich et al. article on the Müller-Lyer illusion (2010). The source for the term “monophasic bias” is apparently Charles Laughlin's chapter “Transpersonal Anthropology” in Roger Walsh's book Paths Beyond Ego (1993). Pierce Salguero, A Lamp Unto Yourself (2025). Resources provided by the interviewee on blackberyl.substack.com: Introduction to the Oxford Handbook of Meditation Pierce Salguero is a transdisciplinary scholar of health humanities who is fascinated by historical and contemporary intersections between Buddhism, medicine, and crosscultural exchange. He has a Ph.D. in History of Medicine from the Johns Hopkins School of Medicine (2010), and teaches Asian history, medicine, and religion at Penn State University's Abington College, located near Philadelphia. www.piercesalguero.com. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/spiritual-practice-and-mindfulness

Ashley Everly is a Toxicologist and the founder of Vaccine.Guide, a one-stop resource on research and information regarding vaccines and the infectious diseases they aim to prevent. In this conversation with Ashely we discuss:The adverse event that led her to investigate vaccinesDiscovering that there is no "happy medium"The woefully inadequate safety studies done on vaccinesThe issue(s) with aluminum adjuvantsOther problematic ingredients...and more!Learn more about Ashley and her work at https://vaccine.guide/ or at https://everlyreport.com/.Support Terrain Theory on Patreon! Our recently-launched member platform gives you access to a ton of free & exclusive content. Check it out: https://www.patreon.com/TerrainTheoryTerrain Theory episodes are not to be taken as medical advice. You are your own primary healthcare provider.If you have a Terrain Transformation story you would like to share, email us at ben@terraintheory.net.Learn more at www.terraintheory.netMusic by Chris Merenda

Featuring perspectives from Dr Kathleen N Moore, Dr David M O'Malley and Dr Alessandro D Santin, moderated by Dr O'Malley, including the following topics: Introduction (0:00) Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Santin (2:17) Available Data with and Practical Application of HER2-Targeted Therapy for Advanced Gynecologic Cancers — Dr O'Malley (30:24) Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr Moore (1:01:53) CME information and select publications

Today I sit down with Miguel Farias, an experimental psychologist and researcher of religion, spirituality, and cognition. Together we try to get to the bottom of whether meditation is actually good for you through a comparison of Miguel's research on the adverse effects of meditation with my research on Asian notions of meditation sickness. Along the way, we discuss the limitations of modern Western understandings of consciousness, and explore whether we can develop a more expansive, multifaceted understanding of altered states both pleasant and unpleasant.If you want to hear scholars and practitioners engaging in deep conversations about the dark side of Asian religions and medicines, then subscribe to Black Beryl wherever you get your podcasts. You can also check out our members-only benefits on blackberyl.substack.com. Enjoy the show!Resources mentioned:Miguel Farias and Catherine Wikholm, The Buddha Pill: Can Meditation Change You? (2019).Miguel Farias, Oxford Handbook of Meditation (2022).Miguel Farias et al, “Adverse Events in Meditation Practices and Meditation-based Therapies: A Systematic Review” (2021).Pierce Salguero, “‘Meditation Sickness' in Medieval Chinese Buddhism and the Contemporary West” (2023). Peter Berger, The Homeless Mind (1973).Joseph Henrich et al. article on the Müller-Lyer illusion (2010).The source for the term “monophasic bias” is apparently Charles Laughlin's chapter “Transpersonal Anthropology” in Roger Walsh's book Paths Beyond Ego (1993).Pierce Salguero, A Lamp Unto Yourself (2025).Resources provided by the interviewee on blackberyl.substack.com:Introduction to the Oxford Handbook of Meditation

In this episode, Dr. Stephen Hussey challenges the mainstream view of heart health, explaining why the heart is not a pump and how blood actually moves through the body. He explores the real causes of heart disease, the impact of structured water on vascular health, and how the heart influences the human biofield and soul connection. Dr. Hussey also discusses the negative effects of common heart medications and why heart-related issues have been increasing in recent years. For more details, links, and resources mentioned in this episode, visit our website: https://thewayfwrd.com To watch, visit YouTube: https://youtu.be/KL68_0b-nrg Connect with Dr. Stephen Hussey: Website – https://resourceyourhealth.com/ Use code WAYFORWARD for 15% off courses Related Link:  Explaining the Mechanism of Adverse Events from Covid mRNA Injections and How to Heal from Them https://resourceyourhealth.com/explaining-the-adverse-events-from-covid-mrna-injections-and-how-to-heal-from-them/ The Way Forward podcast is sponsored by: New Biology Clinic: Experience individually tailored terrain-based health services with virtual consults, practitioner livestreams, movement classes, and more. The New Biology Clinic's motivation is to make you healthy and keep you that way. Visit https://NewBiologyClinic.com and enter code TheWayForward for $50 off your activation fee. Members of The Way Forward get the full activation fee waived. Become a member of The Way Forward here: https://thewayfwrd.com/membership-sign-up/ ————————— RMDY Collective: Dedicated to making homeopathy accessible with high-quality remedies and hands-on training. Discover how this holistic approach supports natural healing and empowers you to take charge of your wellness.  Explore more at RMDY Collective at https://rmdycollective.org/?bg_ref=MKho6KZowa Enroll in RMDY Academy at https://rmdyacademy.org/?bg_ref=MKho6KZowa ————————— RA Optics: Block harmful blue light during the day and at night, optimize your biology with RA Optics. Their lenses are developed with leading experts, using advanced light-filtering technology, and their handcrafted frames offer both quality and style. Check out  Raoptics.com/twf10 and get 10% off your order. ————————— Confluence 2025: Confluence 2025 is a transformative gathering on a regenerative farm near San Antonio, TX, where community, health, and freedom meet. Join us for workshops, live music, and a chance to connect deeply with nature. Use promo code TWF10 for a 10% discount on your tickets. Join us at https://www.confluenceevent.com/

This special issue of JACC is dedicated to the essential role of cardiovascular surgery in advancing modern cardiology.

In this 302nd episode I interview Dr. David Broussard, a cardiac anesthesiologist and Chair of Anesthesiology at Ochsner Medical Center in New Orleans. We discuss his approach to preparing for, and dealing with, adverse events and how to communicate about them to patients and families in a way that builds trust. Our Sponsors:* Check out Factor: https://factormeals.com/accrac50offAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

If you've ever felt frustrated by the fear-driven legal landscape of medicine, this conversation will change the way you think about liability and the future of patient safety. In this episode, Dr. Pensa sits down with trailblazer Richard Boothman, JD, a pioneer in patient safety and transparency, to discuss how the traditional "deny and defend" approach has failed both doctors and patients. We discuss the "Michigan Model," how it came to be, how it works, and how new CMS and ACGME changes may make it our new normal.  Stick around to the end, because Rick's got a story about this model in action that rivals any closing arguments.   Mentioned: A World of Hurt: How Medical Malpractice Fails Everyone   And sign up here for the first-of-its-kind LEAP: Litigation Education and Performance program for clinicians with Dr. Pensa. The course starts March 17 and registration ends on March 10, 2025!    

Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics: Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00) Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53) Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14) Expanding the Spectrum of Targeted Therapy (38:52) Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13) Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35) Identification and Management of Adverse Events with T-DXd (1:20:27) Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02) Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58) CME information and select publications  

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long (@long_brit), we cover immune checkpoint inhibitors and adverse events. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

Happy New Year! This week's episode will go over important details related to immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs), with general management strategies for each of the most common iRAEs.

Guest: Tara Graff, DO, MS Host: Charles Turck, PharmD, BCPS, BCCCP While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it's associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strategies like aggressive hydration, prophylactic use of corticosteroids, early intervention with tocilizumab, and multidisciplinary care. Joining Dr. Charles Turck to share her insights into how we can lower the risks of CAR T-cell therapy is Dr. Tara Graff, a medical oncologist who leads a community-based clinical trial program at Mission Cancer and Blood in Des Moines, Iowa.

This recording features audio versions of January 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Effectiveness of Track Cauterization in Reduction of Adverse Events for Lung Microwave Ablation ReadSelective Lymphatic Duct Embolization for Treatment of Thoracic Lymphatic Flow Disorders in Children: Technical Aspects and Comparison with Thoracic Duct Embolization ReadA Comparison of Postprocedural Hemoglobin in Catheter-Directed Thrombolysis versus Large-Bore Aspiration Thrombectomy for Acute Pulmonary Embolism ReadClinical Outcomes following Invasive Treatment of Femoropopliteal Artery Disease: A Retrospective Single-Center Cohort Study ReadOutcomes of Endovascular Treatment for Infectious Thoracic Aortic Diseases ReadThe Influence of Preablation Embolization Particle Size on the Size of the Microwave Ablation Zone in a Porcine Orthotopic Renal Tumor Model ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Manbir Singh Sandhu, University of California Riverside School of MedicineAudio editor:Manbir Singh Sandhu, University of California Riverside School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Maximillion Hayama, Duke University School of MedicineSonya Choe, University of California Riverside School of MedicineSiddak Dhaliwal, University of Missouri School of MedicineAkumbir Singh Grewal, St. George's University School of MedicineBryan Torres, University of California Riverside School of MedicineJason Hoang, The Ohio State College of MedicineSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Exploring the background of fraud, manipulated data and reactions that led to vaccine skepticism and its mainstreaming, in ThePrint #̦PureScience. Sandhya Ramesh explains.  

Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics: Introduction (0:00) Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44) Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20) Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06) CME information and select publications

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

CONFIRM-2: Artificial Intelligence Enabled Quantitative CT Assessment of Atherosclerosis and Major Adverse Events: A Multi-Center International Registry

Alexandra, founder of "Just the Inserts," transforms complex medical information into accessible resources for the public. Sparked by her daughter's adverse vaccine reaction and her military background, she created a platform that helps Americans understand pharmaceutical product inserts and make informed healthcare decisions. Her investigation revealed concerning practices in the medical system, including limited adverse event reporting and diminishing standards of informed consent. Despite facing challenges when sharing FDA data, Alexandra continues to advocate for medical transparency through her new book and by building networks of healthcare providers committed to thorough patient education. Her work emphasizes the difference between current practices of rushed paperwork and true informed consent, where patients fully understand their medical choices. RADICALLY GENUINE PODCASTDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here—-----------FREE DOWNLOAD! DISTRESS TOLERANCE SKILLS

Send us a textPodcast episodes are fully available to paid subscribers on the M&M Substack and full video versions are free on YouTube. This episode will not be posted on YouTube due to the controversial nature of the content.About the guest: Jessica Rose, PhD is a computational biologist who has been studying and analyzing data from the Vaccine Adverse Event Responding System (VAERS) related to COVID. Episode summary: Nick and Dr. Rose discuss: Vaccine Adverse Event Responding System (VAERS); analysis of VAERS data for COVID; mRNA technology; spike protein persistence & lipid nanoparticles; common adverse events reported for the Pfizer & Moderna shots; myocarditis & menstrual irregularities; IgG4 antibodies, molecular mimicry & autoimmunity; and more.Related episodes:M&M #196: Vaccine Contamination & Fiat Science | Kevin McKernanM&M #100: Infectious Disease, Epidemiology, Pandemics, Health Policy, COVID, Politicization of Science | Jay BhattacharyaSpecial offer: Use MINDMATTERSPECIAL2 for a free 1-year premium subscription to Consensus, an AI-powered research tool that helps you find the best science, faster. ($150 value, limited-time offer).*This content is never meant to serve as medical adviceSupport the showAll episodes (audio & video), show notes, transcripts, and more at the M&M Substack Affiliates: MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. KetoCitra—Ketone body BHB with potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off. Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. Consensus: AI-powered academic research tool. Find & understand the best science, faster. Free 1-year premium sub with code MINDMATTERSPECIAL (exp 12.10.24) Learn all the ways you can support my efforts...

"Safe and effective." With these three words, President Biden and public health officials launched an unprecedented campaign to vaccinate the American public with a novel mRNA technology. Today, we know those words were demonstrably false.In a groundbreaking interview on the Radically Genuine Podcast, Amy Kelly, Chief Operations Officer of Daily Clout and director of the Pfizer Documents Analysis Project, reveals the chilling truth behind the clinical trials. Working with thousands of medical and scientific experts, Kelly's team analyzed over 450,000 pages of Pfizer's own data – documents the FDA initially tried to hide from the public for 75 years.What they uncovered is nothing short of shocking. She is the co-author of The Pfizer Papers: Pfizer's Crimes Against Humanity RADICALLY GENUINE PODCASTDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here—-----------FREE DOWNLOAD! DISTRESS TOLERANCE SKILLS

We have a great round up of some current events and topics that are not getting talked about enough. We chat about the Knife Grab in Manitoba, and the mystery of Samson consultants who got 9 million in 2024 for the Buyback bill for consulting. The Canadian Government consulting business is a tangled web.   We chat about some suspect job openings as part of LMIA, the lack of knack, foreign money flowing fast out of Canada, PBO and the latest carbon tax bull crap. Edmonton's 15 minute city is coming to life - I thought that was just a conspiracy, Doctors hesitant with the MAID service.   We also talk about a personal story with the Jab mandates still going on in BC and the amount of jabs you need to correct Adverse Events from Covid jab with jabs of steroids. Its quite dystopian. More Ivermectin cancer stories, good news on multiple fronts from Peter Sweden, MS starting up 3 mile island for ai based on ai, the Red List, and the Australian movement on the Covid 19 jabs.   To gain access to the second half of show and our Plus feed for audio and podcast please clink the link http://www.grimericaoutlawed.ca/support.   For second half of video (when applicable and audio) go to our Substack and Subscribe. https://grimericaoutlawed.substack.com/ or to our Locals  https://grimericaoutlawed.locals.com/ or Rokfin www.Rokfin.com/Grimerica Patreon https://www.patreon.com/grimericaoutlawed   Support the show directly: https://grimerica.ca/support-2/ Outlawed Canadians YouTube Channel: https://www.youtube.com/@OutlawedCanadians Our Adultbrain Audiobook Podcast and Website: www.adultbrain.ca Our Audiobook Youtube Channel:  https://www.youtube.com/@adultbrainaudiobookpublishing/videos Darren's book www.acanadianshame.ca Check out our next trip/conference/meetup - Contact at the Cabin www.contactatthecabin.com Other affiliated shows: www.grimerica.ca The OG Grimerica Show www.Rokfin.com/Grimerica Our channel on free speech Rokfin Join the chat / hangout with a bunch of fellow Grimericans  Https://t.me.grimerica https://www.guilded.gg/chat/b7af7266-771d-427f-978c-872a7962a6c2?messageId=c1e1c7cd-c6e9-4eaf-abc9-e6ec0be89ff3   Get your Magic Mushrooms delivered from: Champignon Magique  Get Psychedelics online Leave a review on iTunes and/or Stitcher: https://itunes.apple.com/ca/podcast/grimerica-outlawed http://www.stitcher.com/podcast/grimerica-outlawed Sign up for our newsletter http://www.grimerica.ca/news SPAM Graham = and send him your synchronicities, feedback, strange experiences and psychedelic trip reports!! graham@grimerica.com InstaGRAM https://www.instagram.com/the_grimerica_show_podcast/  Purchase swag, with partial proceeds donated to the show www.grimerica.ca/swag Send us a postcard or letter http://www.grimerica.ca/contact/ ART - Napolean Duheme's site http://www.lostbreadcomic.com/  MUSIC Tru Northperception, Felix's Site sirfelix.bandcamp.com    See links to stuff we chatted about during the show: https://www.petersweden.org/p/it-happened-norway-just-rejected?utm_source=post-email-title&publication_id=547128&post_id=149888588&utm_campaign=email-post-title&isFreemail=true&r=24pqe&triedRedirect=true&utm_medium=email https://www.petersweden.org/p/bombshell-slovakia-could-ban-mrna?utm_source=post-email-title&publication_id=547128&post_id=150073127&utm_campaign=email-post-title&isFreemail=true&r=24pqe&triedRedirect=true&utm_medium=email https://www.instagram.com/p/DAM7NvVNoxW/ https://x.com/LeilaniDowding/status/1846556404707934579 https://x.com/Tablesalt13/status/1845665276118876367 https://x.com/SaiKate108/status/1845353260166910053 https://x.com/Mill_Moron/status/1844841736595743012 https://x.com/Tablesalt13/status/1844752664195690594 https://x.com/NyaPfanner/status/1844455593635115237 https://x.com/RetroCoast/status/1841648255790178762 https://x.com/TWilsonOttawa/status/1841860474247242097   Darren's links: https://news.gov.mb.ca/news/index.html?item=65497 https://www.theepochtimes.com/world/canadian-households-worse-off-overall-under-carbon-tax-pbo-report-finds-for-second-time-5739094?utm_source=BN_article_paid&src_src=BN_article_paid&utm_campaign=breaking-2024-10-10-ca&src_cmp=breaking-2024-10-10-ca&utm_medium=email&est=LMpKF3%2FPE9SNgMpyItwgFzL0bZyZbWISpoTCWDQGA6RjhVz2YTxUWmNNiDTv2%2BzM&utm_term=news3&utm_content=3 https://www.newswire.ca/news-releases/millions-more-ontarians-will-live-with-major-illness-by-2040-851491514.html#:~:text=This%20study%20combined%20age%20and,from%201.8%20million%20in%202020. https://www.theepochtimes.com/world/private-forums-show-canadian-doctors-struggle-with-euthanizing-vulnerable-patients-5742397?utm_source=NA_article_paid&src_src=NA_article_paid&utm_campaign=newsalert-2024-10-16-ca&src_cmp=newsalert-2024-10-16-ca&utm_medium=email&est=2qw2dkZe%2F1AepjhhABAmN%2Fe%2FbKbBjgF2y%2Fpg4SAzbUxEzL2rRtsOMaukCsp21I4E&utm_term=news4&utm_content=4   https://www.theepochtimes.com/world/how-edmontons-15-minute-city-plan-may-play-out-5737582?utm_source=TOP5_article_paid&src_src=TOP5_article_paid&utm_campaign=top5-2024-10-12-ca&src_cmp=top5-2024-10-12-ca&utm_medium=email&est=Lac6axs4hYBUrgRMMvTdf5tpw2EF9O4AAIXG0o6lYM17UFXb7RFZ8LYOk7ZekKd1 https://www.theepochtimes.com/epochtv/why-an-emp-attack-is-worse-than-you-think-facts-matter-5730122?utm_source=TOP5_article_paid&src_src=TOP5_article_paid&utm_campaign=top5-2024-10-12-ca&src_cmp=top5-2024-10-12-ca&utm_medium=email&est=zcQdqLW%2FhfAlu2GfTwaTanU0kzzlgRtHMp%2F3m9WNNrl1UX1cXVbT6q5ytOQAZoFc https://x.com/ChildrensHD/status/1845970362971853192 https://petermcculloughmd.substack.com/p/longcovid-19-fatigue-skyrockets-among?utm_campaign=email-half-post&r=2at6hc&utm_source=substack&utm_medium=email https://makismd.substack.com/p/ivermectin-testimonial-thyroid-cancer?utm_source=post-email-title&publication_id=1385328&post_id=150251268&utm_campaign=email-post-title&isFreemail=false&r=2at6hc&triedRedirect=true&utm_medium=email

Dr. Sardari Nia's trial on digital cardiac counseling, presented at EACTS and published in JACC, is a randomized study of 394 patients. It investigated the impact of telemedicine-based prehabilitation to reduce modifiable risk factors in patients awaiting elective cardiac surgery. The results demonstrated a significant 35% reduction in major adverse events, particularly rehospitalizations, highlighting the safety and effectiveness of prehabilitation in improving patient outcomes. This trial also emphasizes empowering patients to take control of their health before surgery, potentially benefiting healthcare on a larger scale.

Audrey Neff speaks with Coverwell CEO, Patrick Tighe, and CMO, Kandis Hughes, to discuss maintaining integrity and ensuring patient safety in the medical aesthetics industry. Throughout the episode, the three delve into the prevalence and nature of adverse events within the elective medical field, highlighting the often unforeseen complications and the gap in patient care that needs addressing. This candid discussion underscores the significance of setting patient expectations, informed consent, proper education, thorough screening processes, and the essential defensive measures practices should adopt—emphasizing the role of businesses like Coverwell in providing a safety net for both practitioners and patients. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/WHB865. CME/CE/AAPA credit will be available until September 24, 2025.Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/WHB865. CME/CE/AAPA credit will be available until September 24, 2025.Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/WHB865. CME/CE/AAPA credit will be available until September 24, 2025.Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/WHB865. CME/CE/AAPA credit will be available until September 24, 2025.Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity has been supported by an independent educational grant from Gilead Sciences, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode, we explore a recent study challenging the safety concerns surrounding haloperidol use in older patients post-surgery. We discuss its implications for managing delirium and compare it to other antipsychotics. Could haloperidol be the unsung hero in our psychopharmacological arsenal? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 59 Comparative Safety of Oral Antipsychotics for Adverse Events in Adults After Surgery

Interview with David B. Yaden, PhD, and Jared T. Hinkle, MD, PhD, authors of Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. Hosted by John Torous, MD, MBI. Related Content: Adverse Events in Studies of Classic Psychedelics

On Episode 43 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the August 2024 issue of Stroke: “Diagnostic Accuracy of Posterior/Anterior Periventricular WMH Ratio to Differentiate CAA From Hypertensive Arteriopathy” and “Statin Overuse in Cerebral Ischemia Without Indications: Systematic Review and Annual US Burden of Adverse Events.” She also interviews Dr. Gang Li about the article “Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke,” published in The New England Journal of Medicine. For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20240726.908961

Imagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to $5,175. You must spend twenty nights literally locked in a research facility. You will be told what to eat, when to eat, and when to sleep. You will share a bedroom with several strangers. Who are you, and why would you choose to take part in this kind of study? This book explores the hidden world of pharmaceutical testing on healthy volunteers. Drawing on two years of fieldwork in clinics across the country and 268 interviews with participants and staff, it illustrates how decisions to take part in such studies are often influenced by poverty and lack of employment opportunities. It shows that healthy participants are typically recruited from African American and Latino/a communities, and that they are often serial participants, who obtain a significant portion of their income from these trials. This book reveals not only how social inequality fundamentally shapes these drug trials, but it also depicts the important validity concerns inherent in this mode of testing new pharmaceuticals. These highly controlled studies bear little resemblance to real-world conditions, and everyone involved is incentivized to game the system, ultimately making new drugs appear safer than they really are. Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals (New York University Press) provides an unprecedented view of the intersection of racial inequalities with pharmaceutical testing, signaling the dangers of this research enterprise to both social justice and public health. Jill A. Fisher is Associate Professor of Social Medicine and Bioethics at the University of North Carolina at Chapel Hill. Claire Clark is a medical educator, historian of medicine, and associate professor in the University of Kentucky's College of Medicine. She teaches and writes about health behavior in historical context. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/african-american-studies

Imagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to $5,175. You must spend twenty nights literally locked in a research facility. You will be told what to eat, when to eat, and when to sleep. You will share a bedroom with several strangers. Who are you, and why would you choose to take part in this kind of study? This book explores the hidden world of pharmaceutical testing on healthy volunteers. Drawing on two years of fieldwork in clinics across the country and 268 interviews with participants and staff, it illustrates how decisions to take part in such studies are often influenced by poverty and lack of employment opportunities. It shows that healthy participants are typically recruited from African American and Latino/a communities, and that they are often serial participants, who obtain a significant portion of their income from these trials. This book reveals not only how social inequality fundamentally shapes these drug trials, but it also depicts the important validity concerns inherent in this mode of testing new pharmaceuticals. These highly controlled studies bear little resemblance to real-world conditions, and everyone involved is incentivized to game the system, ultimately making new drugs appear safer than they really are. Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals (New York University Press) provides an unprecedented view of the intersection of racial inequalities with pharmaceutical testing, signaling the dangers of this research enterprise to both social justice and public health. Jill A. Fisher is Associate Professor of Social Medicine and Bioethics at the University of North Carolina at Chapel Hill. Claire Clark is a medical educator, historian of medicine, and associate professor in the University of Kentucky's College of Medicine. She teaches and writes about health behavior in historical context. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/latino-studies

In this journal club episode, my guest is Dr. Peter Attia, M.D., a Stanford and Johns Hopkins-trained physician focusing on healthspan and lifespan and the host of The Drive podcast. We each present a peer-reviewed scientific paper chosen because it contains novel, interesting, and actionable data. First, we discuss a paper on how bright light exposure at sunrise and throughout the day and dark exposure at night independently improve mental health and can offset some of the major symptoms of mental health disorders such as depression and anxiety. Then, we discuss an article that explores a novel class of immunotherapy treatments to combat cancer. We also discuss some of the new data on low-calorie sweeteners and if they are safe. This episode should be of interest to listeners curious about maximizing their vitality and longevity and to anyone seeking science-supported ways to improve mental health and lifespan. For show notes, including referenced articles and additional resources, please visit hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Eight Sleep: https://www.eightsleep.com/huberman BetterHelp: https://betterhelp.com/huberman Joovv: https://joovv.com/huberman LMNT: https://drinklmnt.com/huberman Momentous: https://livemomentous.com/huberman Timestamps (00:00:00) Dr. Peter Attia, Journal Club (00:02:40) Sponsors: Eight Sleep, BetterHelp & Joovv (00:07:14) Light, Dark & Mental Health; Retina (00:11:16) Outdoor vs. Indoor Light, Cataracts, Sunglasses (00:16:17) Tools: Sunrise & Sunsets, Circadian Rhythm; Midday Light (00:24:55) Tools: Night & Light Exposure; Waking Before Sunrise (00:31:05) Article #1, Light/Dark Exposure & Mental Health (00:36:50) Sponsor: AG1 (00:38:18) Odds Ratio, Hazard Ratio (00:45:43) Night vs. Daylight Exposure, Mental Health Disorders (00:51:35) Major Depression & Light Exposure; Error Bars & Significance (00:59:15) Sponsor: LMNT (01:00:39) Prescriptions; Environmental & Artificial Light; Red Lights (01:08:14) Nighttime Light Exposure; Sleep Trackers & Belief Effects (01:13:54) Light Directionality, Phone, Night (01:17:21) Light Wavelengths & Sensors; Sunglasses (01:20:58) Hawthorne Effect, Reverse Causality, Genetics (01:26:26) Artificial Sweeteners, Appetite (01:31:16) Natural Light Cycles, Circadian Rhythm & Mental Health (01:39:53) Article #2, Immune System & Cancer (01:43:18) T-Cell Activation; Viruses (01:50:41) Autoimmunity; Cancer & Immune System Evasion (02:00:09) Checkpoint Inhibitors, CTLA-4 (02:06:45) Anti-CTLA-4 Study Drug (Ipilimumab), Melanoma (02:12:07) Patient Population, Randomization, GP100 (02:18:09) Response Rate (02:22:52) Overall Survival & Response (02:28:38) Median Survival vs. Overall Survival, Drug Development (02:35:45) Gender & Dose (02:40:32) Adverse Events; Autoimmunity (02:46:42) Pancreatic Cancer; Aging & Immune System Health (02:53:57) Melanoma; Lynch Syndrome, Keytruda (02:58:43) Immunotherapy & Cancer Treatment; Melanoma Risk (03:06:26) Zero-Cost Support, Spotify & Apple Reviews, YouTube Feedback, Sponsors, Momentous, Social Media, Neural Network Newsletter Disclaimer